|Dr. Luke Reid||Chief Exec. Officer||350.37k||N/A||N/A|
|Prof. Gene Tyson||Co-Founder & Non-Exec. Director||80.2k||N/A||N/A|
|Mr. James Heath||CFO & Company Sec.||226.5k||N/A||N/A|
|Prof. Philip Hugenholtz||Co-Founder & Chair of Scientific Advisory Board||N/A||N/A||N/A|
|Mr. Yao Liu||Chief Technology Officer||N/A||N/A||N/A|
|Prof. Lutz Krause||Chief Scientific Officer||N/A||N/A||N/A|
|Mr. Drew Webb||Chief Marketing Officer||N/A||N/A||N/A|
|Prof. Trent Munro||Sr. VP of Therapeutics||N/A||N/A||N/A|
|Dr. Nicola Angel||Head of Laboratory Operations||N/A||N/A||N/A|
|Mr. Bernie Woodcroft||Sr. VP of Platform Solutions||N/A||N/A||N/A|
Microba Life Sciences Limited provides microbiome testing and analysis services for clinicians, consumers, and research customers in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. It offers pathology, therapeutics, and diagnostics services based on the human gut microbiome; Databank, for discovery of therapeutic leads, consumer health innovations, and diagnostic biomarkers; and data-driven therapeutics platform that develops novel monoclonal microbial cell therapies for inflammatory bowel disease, cancer immunotherapy, and autoimmune diseases. The company was incorporated in 2017 and is based in Brisbane, Australia.
Microba Life Sciences Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.